Treatment of Metastatic Melanoma with Lenvatinib + Anti-PD1

Efficacy of Bevacizumab Monotherapy in Treatment of Metastatic Melanoma

NCT00139360 ·Status: COMPLETED ·Phase: PHASE2

A Comparison of Nivolumab-based Treatments in a Real-world PD-L1 Positive Metastatic Melanoma Population in the US

NCT03732560 ·Status: COMPLETED

Masitinib in Non-Resectable or Metastatic Stage 3/4 Melanoma Carrying a Mutation in the Juxta Membrane Domain of c-Kit

NCT01280565 ·Status: TERMINATED ·Phase: PHASE3

Genasense, Carboplatin, Paclitaxel (GCP) Combination in Uveal Melanoma

NCT01200342 ·Status: TERMINATED ·Phase: PHASE2

Follow-up of a National Cohort of Melanoma Resectable Stage II, Stage III or IV Patients or Unresectable Primary

NCT02828202 ·Status: RECRUITING

Intralesional PV-10 Chemoablation of Metastatic Melanoma

NCT00219843 ·Status: COMPLETED ·Phase: PHASE1

Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.

NCT05727904 ·Status: RECRUITING ·Phase: PHASE3

Lenvatinib and Pembrolizumab in Resectable Mucosal Melanoma

NCT04622566 ·Status: UNKNOWN ·Phase: PHASE2

Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma

NCT04955743 ·Status: TERMINATED ·Phase: PHASE2

Neoadjuvant Treatment Associated With Maintenance Therapy by Anti-PD1 Immunotherapy in Patients With Resectable Head and Neck Mucosal Melanoma

NCT03313206 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma

NCT06624644 ·Status: RECRUITING ·Phase: PHASE2/PHASE3

Immune Modulation Study in Patients With Metastatic Melanoma Treated With Anti-PD1 Monoclonal Antibodies

NCT02626065 ·Status: COMPLETED ·Phase: PHASE4

A Phase I Study of LXS196 in Patients With Metastatic Uveal Melanoma.

NCT02601378 ·Status: TERMINATED ·Phase: PHASE1

Study of PAC-1 and Entrectinib for Patients With Metastatic Uveal Melanoma

NCT04589832 ·Status: TERMINATED ·Phase: PHASE1/PHASE2

MB-CART20.1 Melanoma

NCT03893019 ·Status: TERMINATED ·Phase: EARLY_PHASE1

Real-world Evaluation of the Impact of Baseline Metastases on Clinical Outcomes Among BRAF Positive Metastatic Melanoma Patients

NCT05984615 ·Status: COMPLETED

A Single Arm Trial Evaluating the Efficacy and Safety of EVX-01 in Combination With Pembrolizumab in Adults With Unresectable or Metastatic Melanoma

NCT05309421 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

A Phase 1b Trial to Evaluate Safety of MB097 in Combination With Pembrolizumab in Melanoma Patients

NCT06540391 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1

SBRT as a Vaccination for Metastatic Melanoma

NCT04042506 ·Status: WITHDRAWN ·Phase: PHASE2

Phase 1 Study of MPC-6827 and Temozolomide in Metastatic Melanoma

NCT00609011 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Phase 1b Safety Study of CMB305 in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1

NCT02387125 ·Status: TERMINATED ·Phase: PHASE1

Study of Alterations in Tumor Metabolism Associated With the Development of Immunotherapy Resistance in Melanoma

NCT05307289 ·Status: RECRUITING ·Phase: NA

A Study to Test the Benefit of a New Anti-cancer Treatment in Patients With Unresectable Advanced Melanoma

NCT00942162 ·Status: COMPLETED ·Phase: PHASE2

A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel

NCT06940739 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

Study to Evaluate Impact® as Support to Anti PD1 or Anti PD1 Based Regimen Treatment in Patients With Inoperable Locally Advanced or Metastatic Melanoma

NCT06880198 ·Status: RECRUITING ·Phase: NA